Article Information
- September 14, 2020.
Article Versions
- You are currently viewing Version 1 of this article (September 14, 2020 - 12:07).
- Version 2 (February 8, 2022 - 07:25).
- View Version 3, the most recent version of this article.
Author Information
- Theodore P. Braun1,3,*,
- Joseph Estabrook2,*,
- Daniel J. Coleman1,
- Zachary Schonrock1,
- Brittany M. Smith1,
- Trevor Enright2,
- Cody Coblentz1,
- Rowan Callahan1,
- Hisham Mohammed2,
- Brian J. Druker1,3,
- Theresa A. Lusardi2,# and
- Julia E. Maxson1,3,#
- 1Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, 97239, USA
- 2Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, Oregon, 97239, USA
- 3Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, Oregon, 97239, USA
- ↵#Co-corresponding authors Correspondence: Julia E. Maxson, Knight Cancer Institute, 3181 SW Sam Jackson Pk. Rd., KR-HEM, Portland, Oregon, 97239, maxsonj{at}ohsu.edu, Theresa A. Lusardi, Cancer Early Detection Advanced Research Center, 3181 SW Sam Jackson Pk. Rd., KR-CEDR, Portland, Oregon, 97239, lusardi{at}ohsu.edu
Competing Interests B.J.D. potential competing interests-- SAB: Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, Novartis, Gilead Sciences (inactive), Monojul (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, EnLiven Therapeutics, Iterion Therapeutics, Third Coast Therapeutics, GRAIL (SAB inactive); Scientific Founder: MolecularMD (inactive, acquired by ICON); Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Founder: VB Therapeutics; Research Funding: EnLiven Therapeutics; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license and one CytoImage, Inc. exclusive license). The remaining authors have no conflicts to report.